Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study.

NCT00040443 is registered in ClinicalTrials.gov with RespireRx as lead sponsor.

NCT NCT00040443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study.
Lead sponsor
RespireRx
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
June 30, 2004
Enrollment
175 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment